Tencent-backed Grail Inc, a US- and Hong Kong-based healthcare firm that seeks to detect cancer at its curable stage, has raised $300 million in an oversubscribed Series C financing round joined by Chinese investors, including venture capital firm Sequoia Capital China.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
